Applied DNA Sciences Inc (APDN)

[RodeKroet]

ans some more on the subject of Phase I and volunteers, emphasizing the lineardna advantages are hightlighted:

A unique and innovative vaccine compared to traditional technological platforms: "Usually vaccines require live viruses, which must be cultivated and therefore need a very complex production chain - explains Paolo Bonfanti, associate professor of Infectious Diseases of Bicocca and director of the infectious diseases department of the San Gerardo hospital -. "Our" vaccine, on the other hand, is based on the DNA of the virus: a fragment of DNA is injected into the muscle and promotes the synthesis of a portion of the virus's Spike protein,


A genetic type vaccine that not only «has a series of production and conservation advantages», But uses a technological platform that ensures the repeatability of vaccination if the response is not lasting. And compared to other vaccines it can be easily and quickly adaptable in case the virus changes its genetic code over time